Cargando…

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes....

Descripción completa

Detalles Bibliográficos
Autores principales: Banach, Bailey B., Cerutti, Gabriele, Fahad, Ahmed S., Shen, Chen-Hsiang, Oliveira De Souza, Matheus, Katsamba, Phinikoula S., Tsybovsky, Yaroslav, Wang, Pengfei, Nair, Manoj S., Huang, Yaoxing, Francino-Urdániz, Irene M., Steiner, Paul J., Gutiérrez-González, Matías, Liu, Lihong, López Acevedo, Sheila N., Nazzari, Alexandra F., Wolfe, Jacy R., Luo, Yang, Olia, Adam S., Teng, I-Ting, Yu, Jian, Zhou, Tongqing, Reddem, Eswar R., Bimela, Jude, Pan, Xiaoli, Madan, Bharat, Laflin, Amy D., Nimrania, Rajani, Yuen, Kwok-Yung, Whitehead, Timothy A., Ho, David D., Kwong, Peter D., Shapiro, Lawrence, DeKosky, Brandon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479507/
https://www.ncbi.nlm.nih.gov/pubmed/34587480
http://dx.doi.org/10.1016/j.celrep.2021.109771
Descripción
Sumario:Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public antibody response encoded by IGHV3-53/IGHV3-66 genes. Sequence and structural analyses of 910-30 and related antibodies explore how class recognition features correlate with SARS-CoV-2 neutralization. Cryo-EM structures of 910-30 bound to the SARS-CoV-2 spike trimer reveal binding interactions and its ability to disassemble spike. Despite heavy-chain sequence similarity, biophysical analyses of IGHV3-53/3-66-encoded antibodies highlight the importance of native heavy:light pairings for ACE2-binding competition and SARS-CoV-2 neutralization. We develop paired heavy:light class sequence signatures and determine antibody precursor prevalence to be ∼1 in 44,000 human B cells, consistent with public antibody identification in several convalescent COVID-19 patients. These class signatures reveal genetic, structural, and functional immune features that are helpful in accelerating antibody-based medical interventions for SARS-CoV-2.